CN101537188A - Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound - Google Patents
Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound Download PDFInfo
- Publication number
- CN101537188A CN101537188A CN200810084682A CN200810084682A CN101537188A CN 101537188 A CN101537188 A CN 101537188A CN 200810084682 A CN200810084682 A CN 200810084682A CN 200810084682 A CN200810084682 A CN 200810084682A CN 101537188 A CN101537188 A CN 101537188A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- pinocembrin
- injection
- derivant clathrate
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound, wherein cyclodextrin or a cyclodextrin derivative is used to include the pinocembrin. The inclusion compound contains the pinocembrin and the cyclodextrin or cyclodextrin derivative in a molar ratio of 1:1-100. The inclusion compound can improve the water solubility of the pinocembrin and give good play of the therapeutic action of the pinocembrin. The inclusion compound is suitable for the preparation of sold dosage forms and liquid dosage forms required by clinics, including infusion solution, water injection, powder injection, oral solution, syrup, tablets, capsules, granules and dispersible tablets. The inclusion compound can be used for preparing drugs for preventing and\or treating cardiovascular and cerebrovascular diseases, particularly brain stroke, as well as drugs for preventing and\or treating bacterial and\or fungal infections.
Description
Technical field
The present invention relates to pinocembrin and cyclodextrin or cyclodextrin derivant clathrate, its preparation method, contain the pharmaceutical composition of this class pinocembrin and cyclodextrin or cyclodextrin derivant clathrate and in the purposes of preparation in the medicine.Belong to medical technical field.
Background technology
Pinocembrin (pinocembrin), have another name called pinocembrin, give birth to the pine element, chemical name 5, and 7-dihydroxy flavanone (5,7-Dihydroxyflavanone), 2,3-dihydro-5,7-dihydroxy-2-phenyl-4H-1-.alpha.-5:6-benzopyran-4-ketone (2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one), be a kind of water-fast flavanone kind composition, structure is as follows:
Contain a chiral centre in the pinocembrin chemical constitution, natural pinocembrin stereochemical structure is the S configuration, specific optical rotation [α]
D 15For-45.3 (c, 0.9, acetone is solvent).
(S)-pinocembrin is a kind of natural product that extracts from propolis (propolis).Nut pine, also found this chemical compound (CombinedChemical Dictionary 2004) in the extract of a lot of plants such as eucalyptus leaves, Radix Acaciae senegalis in addition.Pinocembrin except that from propolis, separate obtain, nut pine, Eucalyptus, red raise etc. also separablely in the plant goes out this chemical compound, but content is all very low, and pinocembrin also can obtain by synthetic now, this makes (the Cheng Yonghao that come true in a large number of pinocembrin, Duan Yabo, Qi Yan, Guo Xiao Yun, Tong Yuanfeng, Du Guanhua, Wu Song, chemical reagent.2006，28(7)：437)。
The bibliographical information pinocembrin especially shows higher antibacterial effect (Hyun Koo, Pedro L.Rosalen to some Resistant strains to multiple malignant bacteria and fungus sensitivity, Jaime A.Cury, Yong K.Park, andWilliam H.Bowen, Antimicrob.Agents ﹠amp; Chemother.2002,46 (5), 1302-1309).We find that through a large amount of pharmacological testings left-handed pinocembrin has better curative effect to apoplexy, and toxic and side effects very low (Chinese patent 200410037860.9); The activity of synthesising racemation pinocembrin is suitable with left-handed pinocembrin, thereby indirect proof dextrorotation pinocembrin is similar to the pharmacological action of levo form.Pharmacodynamics and toxicological study show, intravenous injection and intraperitoneal injection LD
50Greater than 700 mg/kg, high more than 100 times than effective dose.Therefore, pinocembrin effective, toxicity is little, and pharmacological action relatively has remarkable advantages with existing similar medicine, and indication is multiple disease, has good market prospect.
Because pinocembrin is water insoluble, oral absorption is relatively poor, all has certain difficulty as oral or drug administration by injection.During especially for acute diseases such as treatment apoplexy, need employed pharmaceutical preparation can reach rapid release, quick acting, adopting intravenous injection is the most popular method for the treatment of acute disease clinically.And pinocembrin is made injection, must at first solve its water-fast problem.
Summary of the invention
Water insoluble for pinocembrin in the solution prior art, oral absorption is relatively poor, is difficult to the technical problem of oral or drug administration by injection, the invention provides following technical scheme:
The invention provides a kind of pinocembrin and cyclodextrin or cyclodextrin derivant clathrate
The invention provides the method for this class pinocembrin and cyclodextrin of preparation or cyclodextrin derivant clathrate
The invention provides the pharmaceutical composition that contains this class pinocembrin and cyclodextrin or cyclodextrin derivant clathrate
The invention provides the purposes of going back this class pinocembrin and cyclodextrin or cyclodextrin derivant clathrate.
Particularly, in order to realize purpose of the present invention, adopt following technical scheme: a kind of pinocembrin and cyclodextrin or cyclodextrin derivant clathrate: contain pinocembrin and cyclodextrin or cyclodextrin derivative, the molecule mol ratio of pinocembrin and cyclodextrin or cyclodextrin derivative is 1: 1～1: 100; Preferred molecule mol ratio is 1: 1～1: 10.
Described pinocembrin is selected from left-handed pinocembrin, dextrorotation pinocembrin, raceme pinocembrin;
Described cyclodextrin comprises, but is not limited to alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin; Beta-schardinger dextrin-preferably.
Described cyclodextrin derivative comprises, but is not limited to hydroxyethyl-, HP-, dihydroxypropyl-beta-schardinger dextrin-, methyl-beta-schardinger dextrin-, glucose-cyclodextrin, maltose-cyclodextrin, maltotriose-cyclodextrin, carboxymethyl-cyclodextrin, sulfoalkyl-cyclodextrin; HP-preferably.
This clathrate of pinocembrin and cyclodextrin of the present invention or cyclodextrin derivant clathrate can be a liquid or solid, can be developed to clinical multiple solid dosage forms and the liquid dosage form that is suitable for.
The present invention prepares the following technical scheme of employing of pinocembrin and cyclodextrin or cyclodextrin derivant clathrate:
With solvent in cyclodextrin or the cyclodextrin derivative adding, making the weight concentration scope is 1～60%, and preferred 5～60% cyclodextrin or the solution of cyclodextrin derivative or suspension add pinocembrin, stir or ground and mixed, promptly get liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate.Liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate can be solution or suspension, stir to clarify transparently, promptly get liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate solution.
Pinocembrin and cyclodextrin or the lyophilization of cyclodextrin derivant clathrate solution or spray drying or distillation concentrated to remove desolvate, promptly get solid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate.
In preparation solid pinocembrin dextrin or the cyclodextrin derivant clathrate process, liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate solution can also be concentrated into dextrin or cyclodextrin derivative weight concentration scope earlier at 10～15% solution, carry out lyophilization again, promptly get solid pinocembrin dextrin or cyclodextrin derivant clathrate.
The preparation method of pinocembrin and cyclodextrin or cyclodextrin derivant clathrate among the present invention, also can be that cyclodextrin or cyclodextrin derivative are placed colloid mill or mortar, adding an amount of suitable solvent stirs, make into pastel, pinocembrin is added in the above-mentioned pastel, ground 1～5 hour, get the viscous pastes of homogeneous, filter, concentrate or lyophilization, promptly get solid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate.
It is at least a that the suitable solvent of dissolving cyclodextrin or cyclodextrin derivative is selected from water, ethanol, methanol, propanol, isopropyl alcohol, ethylene glycol, glycerol, acetone, comprises two or more mixed solvent, wherein water preferably.
Add pinocembrin in the preparation and can be the pinocembrin solid or with the pinocembrin solution of an amount of organic solvent dissolution.
The invention provides a kind of pharmaceutical composition, it comprises acceptable carrier on pinocembrin and cyclodextrin or cyclodextrin derivant clathrate and the pharmacopedics.Pinocembrin and cyclodextrin of the present invention or cyclodextrin derivant clathrate can adopt the known method of this area professional, make the suitable type of service or the dosage form that can be used as the human drug use.。The single dose specification is for containing active medicine pinocembrin 1-1000mg, and preferred single dose specification is for containing active medicine pinocembrin 50-250mg.
Described pharmaceutical composition, including but not limited to, liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate are directly used in liquid dosage forms such as the transfusion, liquid drugs injection, powder pin, oral liquid, syrup of preparation; Solid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate are made multiple solid dosage formss such as tablet, capsule, granule, dispersible tablet, oral cavity disintegration tablet, buccal tablet.
Preferred liquid dosage form comprises the injection of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion, and the concentration of injection is 0.01～3% (g/ml), and the pH value of injection is 3～10; Can contain pH adjustment agent such as sodium chloride, glucose isosmoticity regulator and hydrochloric acid, sodium hydroxide in the injection.
Described injectable powder comprises the injectable powder of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion, and the pH value after the injectable powder dissolving is 3～10, can contain pH such as proppant such as mannitol, lactose and hydrochloric acid, sodium hydroxide in the injection and adjust.
Beneficial effect of the present invention:
By cyclodextrin or cyclodextrin derivative pinocembrin is carried out enclose, the pinocembrin molecule is embedded in the tubular structure of cyclodextrin or cyclodextrin derivative molecule, become the clathrate of pinocembrin and cyclodextrin or cyclodextrin derivative, thereby improved the water solublity of pinocembrin.In the time of 25 ℃, the dissolubility of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion in water can reach 2000mg/100ml after measured.
Pinocembrin and cyclodextrin of the present invention or cyclodextrin derivant clathrate make this active component of pinocembrin directly apply to solid, liquid dosage form with the form of clathrate.Cyclodextrin or cyclodextrin derivative are the less water solublity pharmaceutic adjuvants of a kind of toxicity, are suitable for making multiple liquid preparation and solid preparation with the pinocembrin and cyclodextrin or the cyclodextrin derivant clathrate of its preparation.Pinocembrin and cyclodextrin of the present invention or cyclodextrin derivant clathrate have good water solubility, characteristics that blood vessel irritation is little, are particularly useful for making liquid preparation.It is low to have solved the pinocembrin water solublity, can not be directly used in liquid dosage form, especially the technical problem of injection type.In addition owing to improved water solublity, have the advantages that with the solid preparation of its preparation disintegrate is fast, stripping good, bioavailability is high, be more conducive to clinical practice.
The acute toxicity tests shows: the cyclodextrin clathrate of pinocembrin of the present invention, and for the LD of mouse mainline
50Greater than 700 mg/kg, high more than 100 times than effective dose, and do not see local excitation.The cyclodextrin clathrate safety that pinocembrin of the present invention is described is good, is fit to be prepared into injection type.
Pharmacological tests shows: the cyclodextrin clathrate of pinocembrin of the present invention can improve the neuroethology damage that the rat acute focal cerebral ischemia causes; Alleviate the decline degree of cortex middle cerebral artery supply area cerebral blood flow.Can prepare prevention and or the treatment cardiovascular and cerebrovascular diseases medicament, described cardiovascular and cerebrovascular disease is apoplexy preferably.
Pinocembrin is to multiple malignant bacteria and fungus sensitivity in the prior art, especially some Resistant strains are shown higher antibacterial effect, thus inference pinocembrin and cyclodextrin of the present invention or cyclodextrin derivant clathrate can prepare prevention and or the treatment antibacterial and or the fungal infection medicine.
Description of drawings
Fig. 1 .DL0108 is to the influence of MCAO surgical injury rat Bederson scoring
Fig. 2 .DL0108 is to the influence of MCAO surgical injury animal nerve symptom scoring
The Rcbf value (A) of the different time sections in cortex medium-sized artery blood supply district behind Fig. 3 .MCAO surgical injury.
Compound D L0108 is to the influence (B) of MCAO surgical injury rat Rcbf value.
Fig. 1-Fig. 3, data are represented with meansigma methods ± S.E.M. analyzes and passes through Dunett ' s check by single factor ANOVA, and n=10.##P＜0.01vs. blank group,
*P＜0.05vs. solvent control group.
The specific embodiment
Technical scheme for a better understanding of the present invention, the spy provides following examples.But can not be interpreted as any limitation of the invention.Those skilled in the art can make various changes to disclosed technical scheme of the present invention, and this change also belongs to scope of the present invention.
Embodiment 1: preparation liquid pinocembrin hydroxypropyl-beta-cyclodextrin inclusion solution
(1) takes by weighing the 40g HP-, pour in the 400ml distilled water stirring and dissolving into;
(2) take by weighing pinocembrin 1g in addition, add the 20ml anhydrous alcohol solution, this solution is poured in the above-mentioned HP-solution;
(3) mixed liquor stirred 20 minutes down at 40～50 ℃ with the magnetic agitation method, observed solution to clear, promptly got pinocembrin HP-derivative clathrate solution.
Embodiment 2: preparation solid pinocembrin hydroxypropyl-beta-cyclodextrin inclusion
(1), (2), (3) are with embodiment 1.
(4) pinocembrin HP-derivative clathrate solution is carried out lyophilization again, promptly get solid pinocembrin hydroxypropyl-beta-cyclodextrin inclusion.
Embodiment 3: preparation solid pinocembrin hydroxypropyl-beta-cyclodextrin inclusion
(1) takes by weighing the 20g HP-, put into mortar and add the 100ml distilled water, grind and make into pasty state;
(2) take by weighing pinocembrin 3g in addition, add the 20ml anhydrous alcohol solution, this solution is poured in the above-mentioned HP-solution;
(3) mixed liquor was ground 2 hours, obtain the homogeneous pastel, filter, evaporated under reduced pressure promptly gets solid pinocembrin and cyclodextrin derivative clathrate.
Embodiment 4: the sodium chloride transfusion of preparation pinocembrin hydroxypropyl-beta-cyclodextrin inclusion
(1) take by weighing the 20g HP-, pour in the 200ml distilled water, stirring and dissolving adds the 0.5g transfusion and uses active carbon, is heated with stirring to 80 ℃, is incubated 15 minutes, filtering decarbonization;
(2) take by weighing pinocembrin 2g in addition, add the 20ml anhydrous alcohol solution, this solution is poured in the above-mentioned HP-solution;
(3) mixed liquor stirred 20 minutes down at 40～50 ℃ with the magnetic agitation method, observed solution to clear, obtained pinocembrin HP-derivative clathrate solution.
(4) the inclusion complex in solution moisturizing adds sodium chloride for injection 7～8g to 800ml, regulates pH8～9, and regulates PH to 3.5～7 with the hydrochloric acid of 0.05M or the sodium hydroxide of 0.05M, and moisturizing adds 0.1g injection active carbon to 1000ml, stirs 20 minutes.
(5) solution takes off 115 ℃ of charcoal fills, and 30 minutes pressure sterilizings promptly.
Embodiment 5: the glucose infusion liquid of preparation pinocembrin hydroxypropyl-beta-cyclodextrin inclusion
(1), (2), (3) are with embodiment 4.
(4) take by weighing glucose for injection 50g, add the water stirring and dissolving and make volume reach 100ml, add the 0.1g active carbon, heat and littlely boiled filtering decarbonization 15 minutes.
(5) Glucose Liquid is poured in the inclusion complex in solution, and moisturizing is regulated pH to 6-7 to 800ml with the hydrochloric acid of 0.05M or the sodium hydroxide of 0.05M, and moisturizing adds 0.1g injection active carbon to 1000ml, stirs 20 minutes.
(6) solution carries out coarse filtration, fine straining with filter or sand filtration rod (aperture 1.0 μ m, 0.45 μ m, 0.22 μ m) respectively, and fill is 115 ℃ then, and 30 minutes pressure sterilizings promptly.
Embodiment 6: prepare aseptic powder injection with the pinocembrin hydroxypropyl-beta-cyclodextrin inclusion
(1) indoor in the sterile working, take by weighing the 40g HP-, be dissolved in water into 80ml, add the 0.1g active carbon, heat and littlely boiled filtering decarbonization 15 minutes.
(2) take by weighing pinocembrin 1g in addition, add the 20ml anhydrous alcohol solution, this solution is poured in the above-mentioned HP-solution;
(3) mixed liquor stirred 20 minutes down at 40～50 ℃ with the magnetic agitation method, stirred, and observed solution to clear, obtained pinocembrin HP-derivative clathrate solution.
(4) the inclusion complex in solution moisturizing is to 100ml, crosses 0.22 μ m filter membrane, is sub-packed in the cillin bottle of 10ml (2～3ml/ bottle), inserts in the freeze dryer, and the lyophilization gland promptly gets aseptic powder injection.
Embodiment 7: use the beta-cyclodextrin inclusion compound pinocembrin
Take by weighing the 40g beta-schardinger dextrin-, add the 100ml distilled water, be heated to 40～50 ℃, make the beta-schardinger dextrin-dissolving, add the 1g pinocembrin with the 20ml anhydrous alcohol solution, magnetic agitation was filtered after 2～3 hours, and lyophilization promptly gets beta-schardinger dextrin-pinocembrin clathrate.
Embodiment 8: the preparation of beta-cyclodextrin inclusion compound pinocembrin oral capsule
Take by weighing beta-cyclodextrin inclusion compound pinocembrin 20g, itself and 80g lactose are pressed equivalent multiplication method mixing, as binding agent system soft material, 20 mesh sieves are granulated with water dissolution HPMC, and 60 ℃ dry down, dried granule is with 30 mesh sieve granulate, carry out the intermediate check, active medicine 50mg/ grain is encapsulated by containing, sampling observation, packing, promptly.
Embodiment 9: the preparation of beta-cyclodextrin inclusion compound pinocembrin oral tablet
Take by weighing beta-cyclodextrin inclusion compound pinocembrin 20g, with itself and 80g lactose and 5g carboxymethyl starch sodium by equivalent multiplication method mixing, with water dissolution HPMC as binding agent system soft material, 20 mesh sieves are granulated, and 60 ℃ dry down, and dried granule is with 30 mesh sieve granulate, add micropowder silica gel 1g, evenly mixed, by containing active medicine 50mg/ sheet tabletting, carry out the intermediate check, encapsulated, sampling observation, packing, promptly.
Pharmacological evaluation
The pinocembrin hydroxypropyl-beta-cyclodextrin inclusion is to the protective effect of rat acute focal cerebral ischemia injury
Test method: the MCAO model method by bibliographical information test (Zhang Juntian chief editor, the modern pharmacology experimental technique, combined publication society of China Concord Medical Science University of Beijing Medical University, in October, 1998 front page
Nervous symptoms scoring (Bederson ' s Value)
The scoring of sham operated rats Animal Behavior Science is 0 minute.Solvent control treated animal neurological scoring meansigma methods is 3.4 ± 0.6 minutes, and wherein, most animals shows as operation offside forelimb inward turning or interior receipts, and lateral compression is stretched strength to pleural muscle and weakened, and the walking of turn-taking or turn-take once in a while is chosen as 3 fens; The forelimb inward turning only appears in the minority animal in addition and drag descends, and is chosen as 2 fens; The individual animal symptom is heavier, lacks autonomic activities, is chosen as 4 fens.
Chemical compound pinocembrin hydroxypropyl-beta-cyclodextrin inclusion (1mg/kg, 3mg/kg, 10mg/kg, press the cubage of active component pinocembrin, code name DL0108, down with) can significantly improve nerve injury symptom (P＜0.05 behind the animal brain ischemia, P＜0.01), and present dose-effect relationship, and all be better than positive drug nimodipine (see figure 1).
(hang plate experiment) estimated in motor capacity
Sham operated rats rat time of staying meansigma methods on hang plate is 79.3 ± 10.4sec.After the acute cerebral ischemia damage, group of solvents rat time of staying on hang plate obviously shortens, meansigma methods is 4.01 ± 1.42sec, compare with group of solvents, pinocembrin hydroxypropyl-beta-cyclodextrin inclusion (3mg/kg, 10mg/kg) energy significant prolongation animal presents dose-effect relationship in the hang plate time of staying (P＜0.01), and the action effect of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion (3mg/kg, 10mg/kg) dosage group is better than positive control medicine nimodipine (see figure 2).
DL0108 is to the influence of acute cerebral ischemia in rats tissue local cerebral blood flow
The MCAO operation causes local cortex medium-sized artery blood supply district blood flow to quickly fall to the 20%-30% of the preceding basic value of operation, behind the ischemia 24h (before the sacrifice of animal) to be subjected to collateral circulation with the position compensatory, when performing the operation, regional cerebral blood flow rises to some extent, but still being lower than 50% of basic value, the result is shown in figure .3A.
Behind the ischemia 24h of rat cerebral tissue, group of solvents rCBF value is 47.6 ± 5.7% of a basic value, Compound D L0108 (10mg/kg) administration group, nimodipine group rCBF value rise to 25.7 ± 5.6% and 37.7 ± 5.6% of basic value respectively, compare with group of solvents and to have significant difference (P＜0.05), the result is shown in figure .3B.
Above result proves: the pinocembrin hydroxypropyl-beta-cyclodextrin inclusion can improve the neuroethology damage that the rat acute focal cerebral ischemia causes; Alleviate the decline degree of cortex middle cerebral artery supply area cerebral blood flow.
Claims (13)
1, a kind of pinocembrin and cyclodextrin or cyclodextrin derivant clathrate is characterized in that: contain pinocembrin and cyclodextrin or cyclodextrin derivative, the molecule mol ratio of pinocembrin and cyclodextrin or cyclodextrin derivative is 1: 1～1: 100.
2, according to the pinocembrin and cyclodextrin or the cyclodextrin derivant clathrate of claim 1, it is characterized in that: the molecule mol ratio of pinocembrin and cyclodextrin or cyclodextrin derivative is 1: 1～1: 10.
3, according to pinocembrin and cyclodextrin arbitrary among the claim 1-2 or cyclodextrin derivant clathrate, it is characterized in that:
Described pinocembrin is selected from left-handed pinocembrin, dextrorotation pinocembrin, raceme pinocembrin;
Described cyclodextrin is selected from alpha-cyclodextrin, beta-schardinger dextrin-, gamma-cyclodextrin;
Described cyclodextrin derivative is selected from hydroxyethyl-, HP-, dihydroxypropyl-beta-schardinger dextrin-, methyl-beta-schardinger dextrin-, glucose-cyclodextrin, maltose-cyclodextrin, maltotriose-cyclodextrin, carboxymethyl-cyclodextrin, sulfoalkyl-cyclodextrin.
4, the preparation method of liquid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate, it is characterized in that: cyclodextrin or cyclodextrin derivative are added in the solvent, make the weight concentration scope at 1～60% solution or suspension, add pinocembrin, stir or ground and mixed, promptly get pinocembrin and cyclodextrin or cyclodextrin derivant clathrate solution or suspension.
5, the preparation method of solid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate, it is characterized in that:, promptly get solid pinocembrin and cyclodextrin or cyclodextrin derivant clathrate pinocembrin and cyclodextrin or cyclodextrin derivant clathrate solution lyophilization or concentrated except that desolvating.
6, according to described method arbitrary among the claim 4-5, it is characterized in that,
Described solvent is selected from water, ethanol, methanol, propanol, isopropyl alcohol, ethylene glycol, glycerol, the acetone at least a;
Add pinocembrin and can be the pinocembrin solid or with the pinocembrin solution of an amount of organic solvent dissolution.
7, a kind of pharmaceutical composition is characterized in that, comprises among the claim 1-3 acceptable carrier on any one pinocembrin and cyclodextrin or cyclodextrin derivant clathrate and the pharmacopedics.
8, according to the pharmaceutical composition of claim 7, it is characterized in that: described pharmaceutical composition comprises transfusion, liquid drugs injection, powder pin, oral liquid, syrup, tablet, capsule, granule, dispersible tablet, oral cavity disintegration tablet, buccal tablet.
9, a kind of injection of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion, it is characterized in that, the concentration of injection is 0.01～3% (g/ml), and the pH value of injection is 3～10, can contain pH adjustment agent such as sodium chloride, glucose isosmoticity regulator and hydrochloric acid, sodium hydroxide in the injection.
10, a kind of injectable powder of pinocembrin hydroxypropyl-beta-cyclodextrin inclusion is characterized in that, the pH value after the injectable powder dissolving is 3～10, can contain pH such as proppant such as mannitol, lactose and hydrochloric acid, sodium hydroxide in the injection and adjust agent.
11, among the claim 1-3 arbitrary described pinocembrin and cyclodextrin or cyclodextrin derivant clathrate the preparation prevention and or the application of treatment in the cardiovascular and cerebrovascular diseases medicament.
According to the application of claim 11, it is characterized in that 12, described cardiovascular and cerebrovascular disease is an apoplexy.
13, among the claim 1-3 arbitrary described pinocembrin and cyclodextrin or cyclodextrin derivant clathrate the preparation prevention and or the treatment antibacterial and or the fungal infection medicine in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100846823A CN101537188B (en) | 2007-03-21 | 2008-03-18 | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710064572.6 | 2007-03-21 | ||
| CN200710064572 | 2007-03-21 | ||
| CN2008100846823A CN101537188B (en) | 2007-03-21 | 2008-03-18 | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101915795A Division CN102716070A (en) | 2008-03-18 | 2008-03-18 | Pinocembrin and cyclodextrin or cyclodextrin derivative clathrate compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101537188A true CN101537188A (en) | 2009-09-23 |
| CN101537188B CN101537188B (en) | 2012-07-18 |
Family
ID=41120726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100846823A Active CN101537188B (en) | 2007-03-21 | 2008-03-18 | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101537188B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010066199A1 (en) * | 2008-12-11 | 2010-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
| CN101744806B (en) * | 2008-12-11 | 2012-09-12 | 石药集团中奇制药技术（石家庄）有限公司 | Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy |
| CN102988279A (en) * | 2011-09-08 | 2013-03-27 | 石药集团中奇制药技术（石家庄）有限公司 | Pinocembrin and cyclodextrin supermolecular inclusion complex and preparation method thereof |
| CN111330019A (en) * | 2018-12-18 | 2020-06-26 | 中国人民解放军第二军医大学 | Flumazenil clathrate compound and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1285334C (en) * | 2004-05-12 | 2006-11-22 | 中国医学科学院药物研究所 | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell |
| CN1739537A (en) * | 2004-08-26 | 2006-03-01 | 张红军 | Cyclodextrin clathrate of breviscapine and its prepn |
-
2008
- 2008-03-18 CN CN2008100846823A patent/CN101537188B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010066199A1 (en) * | 2008-12-11 | 2010-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
| CN101744806B (en) * | 2008-12-11 | 2012-09-12 | 石药集团中奇制药技术（石家庄）有限公司 | Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy |
| EA022275B1 (en) * | 2008-12-11 | 2015-12-30 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
| CN102988279A (en) * | 2011-09-08 | 2013-03-27 | 石药集团中奇制药技术（石家庄）有限公司 | Pinocembrin and cyclodextrin supermolecular inclusion complex and preparation method thereof |
| CN102988279B (en) * | 2011-09-08 | 2016-06-15 | 石药集团中奇制药技术（石家庄）有限公司 | Pinocembrin and cyclodextrin super molecule inclusion compound and its preparation method |
| CN111330019A (en) * | 2018-12-18 | 2020-06-26 | 中国人民解放军第二军医大学 | Flumazenil clathrate compound and preparation method and application thereof |
| CN111330019B (en) * | 2018-12-18 | 2022-03-15 | 中国人民解放军第二军医大学 | Flumazenil clathrate compound and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101537188B (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005051404A1 (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| JP5413998B2 (en) | Inclusion complex of pinocembrin by cyclodextrin or its derivatives | |
| WO2011079410A1 (en) | Medicinal composition including sunflower extract, preparative method and use thereof | |
| WO2015081703A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN101537188B (en) | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound | |
| WO2015081701A1 (en) | Desmodium styracifolium (osb.) merr. flavonoids capsule, method of preparing same, and application thereof | |
| CN101612188B (en) | Preparation method and product of eucommia bark antihypertensive traditional Chinese medicine sustained-release preparation | |
| JP2010528063A (en) | Method and use for obtaining an extract containing sequoyitol from a plant belonging to the genus Rhododendron, soybean, genus Ginkgo | |
| CN101156863B (en) | A medicine composition for treating cardiac and cerebral vascular disease and its medical usage | |
| CN102233001B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases as well as preparation method and detection method thereof | |
| CN101327289A (en) | Novel uses of day lily and day lily total flavones | |
| CN107746403A (en) | Serial open loop Diterpene class compound and its pharmaceutical composition and its application in pharmacy | |
| CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
| CN102716070A (en) | Pinocembrin and cyclodextrin or cyclodextrin derivative clathrate compound | |
| CN1698774A (en) | Chinese medicinal soft capsule with heat-clearing toxin-removing function and its preparation process | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| CN105687262A (en) | Folium ginkgo tincture and preparing method thereof | |
| CN101249125B (en) | Herbicide composition and its preparation and medicament use | |
| CN100563647C (en) | The Pharmaceutical composition of Herba Erigerontis and sodium tanshinon IIA silate injection | |
| CN102526157B (en) | Application of safflower extract to prevention or treatment of neurodegeneration disease | |
| CN1199650C (en) | Medicine composition of red peony total glucoside for curing cardio-cerebrovascular diseases and its preparation method | |
| CN112870208A (en) | Application of Pubescenoside A in preparation of medicine for preventing and treating myocardial ischemia-reperfusion injury | |
| CN104069066B (en) | Berberine-sodium caprate solid dispersion and application of same in treating diabetes and complications thereof | |
| CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same | |
| CN110279735B (en) | Effective part of Chinese walnut leaf and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |